# Treatment options for liver cirrhosis
The treatment of liver cirrhosis aims to address the underlying cause, prevent further liver damage, relieve symptoms, and prevent serious complications. The approach varies greatly depending on the stage of the disease (compensated or decompensated) and the cause. Below are the main treatment categories.
---
Treatment of the underlying cause
Viral hepatitis
For chronic hepatitis B, medication is typically given to suppress viral replication. This can slow the progression of liver damage.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Antiviral agents (such as nucleos(t)ide analogues) inhibit the multiplication of hepatitis B virus and thereby reduce inflammation in the liver. They are given for a long time or for life. Side effects may include fatigue, headache, and digestive problems. The goal is not to eradicate the virus, but to keep viral activity low to slow the progression of cirrhosis.
For chronic hepatitis C, there are medications that in many cases lead to complete viral eradication.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Direct-acting antiviral agents (DAAs) can completely eliminate hepatitis C virus in most patients, even with cirrhosis present. This treatment lasts several weeks to months. Side effects are usually minimal. Cure of the viral infection can significantly improve liver function and prognosis.
Alcohol-related cirrhosis
Cessation of alcohol use is essential and forms the basis of all further treatment.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Stopping alcohol consumption helps prevent further liver damage and can in some cases lead to improvement of liver function. Guidance by specialists in addiction care and psychological support play an important role. Withdrawal symptoms may occur and require support.
Metabolic fatty liver disease (MASLD/MASH)
In case of overweight and metabolic abnormalities, treatment focuses on weight loss and control of diabetes and cholesterol.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Weight reduction, exercise, and control of associated conditions (type 2 diabetes, high blood pressure, elevated cholesterol) help slow disease progression. This is usually done through dietary advice and medication for underlying conditions.
ResearchediPositive results in clinical studies, not yet standard treatment
Certain diabetes medications (for example, GLP-1 agonists) are currently being investigated for their effect on liver fat and fibrosis. Studies suggest positive effects, but research is not yet complete.
Autoimmune and hereditary liver diseases
For autoimmune hepatitis and primary sclerosing cholangitis, anti-inflammatory agents are used.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Corticosteroids and azathioprine suppress the autoimmune reaction and reduce liver inflammation. These medications require regular monitoring. Side effects may include increased susceptibility to infection, osteoporosis, and weight gain.
---
Prevention and treatment of varices (esophageal vessels)
Patients with advanced cirrhosis can develop bleeding esophageal varices. This is prevented in an early stage.
Beta blockers
ProveniIncluded in official guidelines, or approved by EMA or FDA
Certain beta-blockers lower the pressure in the portal veins and prevent bleeding from varices. They work by lowering heart rate and blood pressure, reducing the amount of blood flowing through the deformed vessels. Side effects include fatigue, low energy, and sometimes breathing problems. These medications are given for a long time.
Endoscopic ligation
ProveniIncluded in official guidelines, or approved by EMA or FDA
When varices are detected, they are sometimes tied off with rubber band(s) during an esophageal examination. This prevents bleeding. The procedure requires sedation. Side effects are rare but may include fever, pain, and very rarely perforation.
---
Treatment of fluid accumulation (ascites) and kidney function disorders
Fluid accumulation in the abdomen is a common problem in decompensated cirrhosis.
Diuretics
ProveniIncluded in official guidelines, or approved by EMA or FDA
Diuretics promote the excretion of fluid through the kidneys. They work by altering salt balance. Side effects may include electrolyte disturbances (low potassium, sodium) and worsening of kidney function; therefore, their use requires regular monitoring.
Albumin infusion
ProveniIncluded in official guidelines, or approved by EMA or FDA
In severe fluid accumulation or certain complications, blood protein (albumin) is given intravenously. This helps fluid excretion through the kidneys. It works in a supportive capacity alongside other treatments.
Transjugular intrahepatic portosystemic shunt (TIPS)
ProveniIncluded in official guidelines, or approved by EMA or FDA
In severe fluid accumulation that does not respond to medication, a TIPS procedure may be performed. A tube is placed in the liver via the vein in the neck, which relieves high pressure in the portal veins. This is an intervention performed under X-ray guidance. Side effects may include bleeding, infection, and (rarely) a type of confusion due to changes in blood circulation.
---
Treatment of infections
Patients with cirrhosis have increased susceptibility to infection. Infections can cause serious complications.
Spontaneous bacterial peritonitis
ProveniIncluded in official guidelines, or approved by EMA or FDA
In infection of fluid accumulation in the abdomen, antibiotics are given. These are administered intravenously or by mouth, depending on severity. Early recognition and treatment are crucial.
Long-term antibiotic prophylaxis
ProveniIncluded in official guidelines, or approved by EMA or FDA
Certain patients with cirrhosis and fluid accumulation receive long-term low-dose antibiotics to prevent bacterial infections. Side effects depend on the specific medication.
---
Treatment of hepatic encephalopathy
Confusion and cognitive problems can occur when the liver can no longer process toxins (especially ammonia).
Lactulose and lactitol
ProveniIncluded in official guidelines, or approved by EMA or FDA
These sugars do not enter the bloodstream and alter gut bacteria in such a way that less ammonia is produced. They work as laxatives and thus also reduce intestinal transit time. Side effects are abdominal cramps, gas formation, and diarrhea.
Rifaxomicin
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is an antibiotic that is effective in the intestine and is not absorbed into the bloodstream. It reduces ammonia-producing bacteria. Side effects are generally minimal.
Branched-chain amino acids
ResearchediPositive results in clinical studies, not yet standard treatment
These special protein components are sometimes given because it is thought that they improve nitrogen metabolism. The evidence for significant benefit is still limited.
---
Supportive treatment and symptom management
Blood pressure medication and kidney protection
ProveniIncluded in official guidelines, or approved by EMA or FDA
Certain blood pressure-lowering medications (ACE inhibitors or ARBs) can protect the kidneys and are given in kidney function disorders. Side effects may include dizziness, cough, and electrolyte disturbances.
Bone protection
ResearchediPositive results in clinical studies, not yet standard treatment
Patients with cirrhosis have increased bone loss and osteoporosis. Calcium supplements, vitamin D, and (in certain cases) bisphosphonates may be given. Studies indicate protective effects, although evidence is not yet complete.
Nutritional interventions
ProveniIncluded in official guidelines, or approved by EMA or FDA
Nutritional guidance is important: adequate protein intake (not too low, but with caution in hepatic encephalopathy), vitamin supplements (especially B vitamins and vitamin D), and salt restriction support the liver and prevent fluid accumulation. A dietitian helps develop an appropriate nutritional pattern.
Sleep quality and wellbeing
ResearchediPositive results in clinical studies, not yet standard treatment
Recent studies show that regular sleep patterns and thereby better wellbeing are associated with better outcomes. Support for sleep hygiene and guidance with sleep problems are part of holistic care.
---
Experimental approaches
MicroRNA therapies
ExperimentaliOngoing in study setting, outcome still unknown
Research is investigating the use of small RNA molecules (microRNAs) that can inhibit liver fibrosis. These approaches are still in early research stages and are not ready for clinical use.
Targeting of specific proteins in hepatic stellate cells
ExperimentaliOngoing in study setting, outcome still unknown
Studies are examining whether inhibiting certain signaling molecules (for example PDGFRB in stellate cells) can prevent fibrosis. This research is ongoing and requires further validation.
---
Transplantation
Liver transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
In end-stage cirrhosis with severe liver failure, liver transplantation is the only curative option. This requires a donor (living or deceased) and lifelong immunosuppression. It is a major operation with serious risks and benefits that are carefully weighed. Suitability is determined based on disease severity, overall health, and donor availability.
---
Regular monitoring
Regardless of which treatment is given, regular check-ups are essential:
ProveniIncluded in official guidelines, or approved by EMA or FDA
Blood tests (liver enzymes, albumin, bilirubin, INR, kidney function and electrolytes), ultrasound or other imaging, and regular clinical assessments help detect complications early and adjust treatment. This remains necessary as long as cirrhosis is present, even if the underlying cause were to be eliminated.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._